[The beta2-adrenergic receptor agonists in the treatment of chronic obstructive pulmonary disease].
Chronic obstructive pulmonary disease (COPD) is considered one of the most common chronic diseases in the world. It is characterized by the progressive reduction of the respiratory parameters, relatively low effectiveness of recommended treatment as well as serious prognosis especially in the group of patients with advanced disease. The beta2-adrenergic receptor agonists are first-line therapeutics in the treatment of COPD patients. Due to their diverse pharmacokinetic characteristic beta2-mimetics are recommended both for regular or "rescue" treatment to prevent or to restrain dyspnea symptoms. This paper evaluates main differences between the mechanism of action and pharmacokinetic profile of the key beta2-mimetics, discusses consequences of those diversities for their the clinical application and potential side effects.
Chorostowska-Wynimko
Joanna
J
Samodzielna Pracowni Diagnostyki, Molekularnej Instytutu Gruźlicy i Chorób Płuc w Warszawie. j.chorostowska@igichp.edu.pl
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000420:Albuterol / Q000031:analogs & derivatives / Q000627:therapeutic use; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D004417:Dyspnea / Q000188:drug therapy / Q000209:etiology; D004983:Ethanolamines / Q000627:therapeutic use; D000068759:Formoterol Fumarate; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications / Q000188:drug therapy*; D000068299:Salmeterol Xinafoate
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D003692:Delayed-Action Preparations; D004983:Ethanolamines; D000068299:Salmeterol Xinafoate; D000420:Albuterol; D000068759:Formoterol Fumarate